Health Economics›Chronic myelomonocytic leukemia›First-line therapy

First-line therapy

Chronic myelomonocytic leukemia · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine and Lenalidomide Variant #01	—	R 20 877	28d	—	—	—	—	—
Azacitidine and Vorinostat Variant #01 Partial	—	R 18 699	28d	—	—	—	—	—
Azacitidine monotherapy Variant #01	—	R 18 699	28d	—	~24.5 mo	—	—	1
Decitabine monotherapy Variant #01	—	R 10 907	42d	—	~10.1 mo	—	—	1
Hydroxyurea monotherapy Variant #01	—	R 278	28d	—	~243.6 mo	—	—	—
Decitabine and cedazuridine monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

6 of 6 regimens shown